Go Deep
Nath Bio-Genes (India) Limited
Nath Bio-Genes (India) Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 25,219 | 7.5 | 0.39 | 0.20 | 138.31 |
| Oct 2026 | 23,942 | 7.5 | 0.39 | 0.20 | 137.79 |
Nath Bio-Genes (India) Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 3,284,042,000.0 | 515,928,000.0 | 659,590,000.0 | 438,496,000.0 |
| Net Profit | 322,618,000.0 | -89,000.0 | 16,049,000.0 | 27,533,000.0 |
| EPS | 17.0 | -0.8 | 0.8 | 1.4 |
Nath Bio-Genes (India) Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 4,451,015,000.0 | 3,649,082,000.0 | 3,326,249,000.0 | 3,013,637,000.0 |
| Net Profit | 416,303,000.0 | 385,996,000.0 | 396,185,000.0 | 350,114,000.0 |
| EPS | 21.9 | 20.3 | 20.8 | 18.4 |
Nath Bio-Genes (India) Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 10,974,288,000.0 | 10,262,075,000.0 | 8,802,306,000.0 | 7,927,969,000.0 | — |
| Total Liabilities | 4,169,699,000.0 | 3,818,203,000.0 | 2,703,119,000.0 | 2,196,235,000.0 | — |
| Total Equity | 6,804,589,000.0 | 6,443,872,000.0 | 6,099,187,000.0 | 5,731,734,000.0 | — |
Owes vs Owns
Nath Bio-Genes (India) Limited owed ₹0.38 for every ₹1 it owned in Mar 2026, up from ₹0.28 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.38× | 0.37× | 0.31× | 0.28× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Nath Bio-Genes (India) Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 6.9%Receivables 7.8%Inventory 41.1%Fixed assets (tangible) 26.1%Intangible assets 0.5%Long-term investments 0.5%Other assets 17.1%
How it's funded — Mar 2026
Short-term debt 11.0%Long-term debt 1.6%Payables 11.9%Other liabilities 13.4%Shareholders' equity 62.0%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 75.5 | 88.5 | 77.1 | 38.0 |
| Receivables | 85.4 | 88.9 | 94.3 | 97.3 |
| Inventory | 450.5 | 338.0 | 230.3 | 207.8 |
| Fixed assets (tangible) | 286.4 | 286.1 | 281.5 | 256.4 |
| Intangible assets | 5.6 | 7.2 | 8.8 | 10.4 |
| Long-term investments | 5.9 | 5.8 | 6.0 | 5.0 |
| Other assets | 188.1 | 211.7 | 182.2 | 177.8 |
| Liabilities & equity | ||||
| Short-term debt | 121.2 | 109.5 | 105.5 | 104.8 |
| Long-term debt | 17.3 | 13.0 | 4.9 | 0.4 |
| Payables | 131.1 | 79.5 | 43.3 | 27.7 |
| Other liabilities | 147.3 | 179.8 | 116.7 | 86.7 |
| Shareholders' equity | 680.5 | 644.4 | 609.9 | 573.2 |
| Net tangible assets | 674.9 | 637.2 | 601.1 | 562.8 |
Nath Bio-Genes (India) Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -125,732,000.0 | 175,813,000.0 | 745,938,000.0 | 383,666,000.0 | — |
| Investing Activities | 34,576,000.0 | -39,621,000.0 | -274,012,000.0 | -28,840,000.0 | — |
| Financing Activities | -37,883,000.0 | -21,300,000.0 | -77,779,000.0 | -16,679,000.0 | — |